MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of investments
$12,000K
Issuance of common stock
in connection with...
$14,988K
Net cash provided by
investing activities
$12,000K
Net cash provided by
financing activities
$9,443K
Canceled cashflow
$5,545K
Net increase in cash
and cash...
$12,354K
Canceled cashflow
$9,089K
Repayment of borrowings
$5,545K
Intangible asset
impairment charge
$67,808K
Net income (loss)
$35,912K
Accounts payable
$5,911K
Other assets
-$1,782K
Stock based
compensation
$1,286K
Other liabilities
$701K
Depreciation and
amortization
$36K
Right of use assets,
operating leases and...
-$28K
Net cash used in
operating activities
-$7,627K
Effect of exchange rate
changes on cash
-$1,462K
Canceled cashflow
$113,464K
Change in the fair value
of contingent...
-$64,330K
Change in fair value of
warrants
-$31,116K
Change in fair value of
debt, net
-$12,197K
Accrued expenses and
other current...
-$7,163K
Prepaid expenses and
other current assets
$3,639K
Gain on settlement of
accounts payable
$2,584K
Amortization of discount on
available-for-sale investments
$62K
Back
Back
Cash Flow
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)
source: myfinsight.com